NEW YORK, May 24 /PRNewswire-FirstCall/ -- Xenomics, Inc. , the source of next-generation medical DNA technologies, today announced that Dr. Samuil Umansky, MD, Ph.D., Xenomics’ Chief Science Officer, and Co-Founder, has been invited to make a presentation regarding Transrenal DNA and its potential impact on global detection of Tuberculosis and other infectious diseases at the 106th General Meeting of the American Society for Microbiology in Orlando, Florida.
Dr. Umansky’s presentation titled “Detection of Transrenal Mycobacterial DNA for Diagnosis and Monitoring of Tuberculosis” is one of the featured topics in “The Clinical Frontier” portion of today’s ASM program devoted to new technologies.
The ASM General Meeting is an annual scientific program which provides a forum for professionals and leaders in the field of microbiological sciences to share new data from research in and consider the most recent trends in healthcare management. Additional information is available at www.asm.org.
“We were pleased to be invited by the ASM to introduce this breakthrough DNA-based diagnostic technology,” said Dr. David Tomei, CEO of Xenomics. “We intend to utilize this platform to develop and commercialize a whole new generation of completely safe, non-invasive, and highly sensitive diagnostic testing products for the detection and monitoring of wide range of infectious diseases and other conditions.”
Xenomics’ proprietary Transrenal DNA diagnostic technology utilizes urine samples, rather than invasive blood or other samples. Fragmented cellular DNA from throughout the body cross the kidney barrier and accumulate in the urine providing vital information about a wide range of conditions inside the body. The Company believes this new technology will foster fundamental improvements in safety, accuracy and functionality of testing in the field of molecular diagnostics, currently a $1.5 billion segment of the healthcare industry.
About Xenomics, Inc.
Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA (Tr-DNA). Xenomics’ patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. Scientists from Xenomics were the first to report that fragments of DNA from normal cell death cross the kidney barrier and can be detected in urine. The Company believes that its technology will open significant new markets in the molecular diagnostics field. Xenomics has three issued U.S. patents covering different applications of the technology for molecular diagnostics and genetic testing and a corresponding allowed European patent for the Company’s prenatal testing applications. The Company has organized a joint venture to conduct research on infectious disease detection with the National Institute for Infectious Diseases (Istituto Nazionale per la Malattie Infettive “Lazarus Spallanzani”) in Rome, in the form of a research and development company called SpaXen Italia, S.R.L. For additional information, please visit www.xenomics.com. Xenomics’ stock trades under the symbol XNOM.OB and is also listed on the Frankfurt Stock Exchange under the symbol XE7.
Forward-Looking Statements
Certain statements made in this press release are forward looking. Such statements are indicated by words such as “expect,” “might,” “should,” “anticipate” and similar words indicating uncertainty in facts and figures. Although Xenomics believes that the expectations reflected in such forward- looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in Xenomics’ Form 10-KSB as filed with the Securities and Exchange Commission on May 16, 2006, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that Xenomics will not obtain approval to market its products, the risk that Xenomics’ technology will not gain market acceptance, the risks associated with dependence upon key personnel, and the need for additional financing.
Xenomics, Inc.
CONTACT: L. David Tomei of Xenomics, Inc., +1-212-297-0808,ldtomei@xenomics.com
Web site: http://www.xenomics.com/
